Continuous Glucose Monitoring for Non-Diabetics: What Physicians Really Think in 2026

Introduction: The CGM Conversation Has Changed

The landscape of personal health monitoring shifted dramatically when the FDA approved the first over-the-counter continuous glucose monitors in 2024. Dexcom Stelo and Abbott Lingo entered the market, putting glucose monitoring in the hands of millions without a prescription for the first time in U.S. history. What was once exclusive to diabetes management became accessible to anyone curious about their metabolic health.

This democratization did not emerge in a vacuum. Biohackers, longevity enthusiasts, and athletes had embraced CGMs since 2017, treating glucose data as a window into performance and aging. By 2026, the market has matured into two distinct tiers: affordable OTC sensors for self-trackers and premium AI-coaching platforms like Levels, Signos, and January AI that transform raw data into personalized metabolic insights.

Yet consumer enthusiasm has outpaced clinical evidence. The 2025 Mass General Brigham study and January 2026 Johns Hopkins findings have forced physicians into a more nuanced conversation about who actually benefits from continuous glucose monitoring. The question doctors are asking in 2026 is not whether non-diabetics can use CGMs. The question is which non-diabetics actually benefit, and how.

This article separates three distinct non-diabetic populations: prediabetics, metabolically at-risk individuals, and healthy optimizers. For each group, physicians have reached different conclusions based on the available evidence.

Understanding the CGM Landscape for Non-Diabetics in 2026

Continuous glucose monitors work through a small sensor inserted under the skin, typically on the upper arm or abdomen. This sensor measures interstitial glucose continuously, transmitting real-time data to a smartphone app where users can track patterns, spikes, and trends throughout the day.

The OTC options available in 2026 include Dexcom Stelo, priced at $89 to $99 per month for two 15-day sensors. Stelo is HSA and FSA eligible and available on Amazon. Abbott’s Lingo and Libre Rio became available on Amazon in February 2025, offering comparable functionality at competitive price points.

The market context reveals substantial growth potential. The U.S. OTC CGM market was valued at approximately $48.6 million in 2024 and is projected to reach $93.5 million by 2033. The broader global CGM market stands at an estimated $15.33 billion in 2026.

Beyond raw glucose data, AI-enhanced platforms represent the next evolution. January AI, named one of TIME’s Best Inventions of 2025, builds a “digital twin” of a user’s metabolism capable of predicting glucose responses up to 33 hours in the future. This predictive capability reduces the need for permanent CGM wear while offering personalized nutritional guidance.

The potential non-diabetic market is enormous. Approximately 96 million U.S. adults, roughly one in three, have prediabetes, and over 80% are unaware of their condition. Only about 12% of American adults are considered metabolically healthy. These statistics explain the commercial interest in wellness-focused CGM applications.

For clinical context, non-diabetic individuals maintain a median Time in Tight Range (TITR, 70 to 140 mg/dL) of 96%. This benchmark helps physicians evaluate CGM data from non-diabetic users and distinguish normal variation from concerning patterns.

What the Research Actually Says: The Landmark Studies Physicians Are Citing

Two major studies have shaped physician opinion on non-diabetic CGM use in 2026. These represent the first large-scale, peer-reviewed attempts to evaluate CGM utility specifically in populations without diabetes.

The 2025 Mass General Brigham Study: A Turning Point

Published in Diabetes Technology and Therapeutics, this study analyzed 972 adults across the glycemic spectrum. The key finding challenged assumptions about CGM utility: while CGM metrics correlate well with HbA1c in people with diabetes, this correlation weakens significantly in prediabetes and disappears entirely in those without diabetes.

The clinical implication is significant. For healthy non-diabetics, CGM readings may not accurately reflect overall blood sugar control. A spike after a meal does not necessarily signal a metabolic problem in someone without diabetes.

Dr. Jorge Rodriguez, one of the study authors, framed CGM data as “not a substitute for HbA1c” for those without diabetes, though it may serve as a behavioral biofeedback tool. The study also called for digital health equity work to ensure diabetes prevention innovation reaches underserved populations, a dimension often overlooked in consumer-focused discussions.

Johns Hopkins Bloomberg School of Public Health: The Gold Standard Question

The January 2026 Johns Hopkins analysis, led by epidemiologist Elizabeth Selvin, delivered a pointed assessment: “All the clinical information about how to interpret and act on the information from CGMs is for people with diabetes.”

This interpretive gap presents a fundamental challenge. The clinical reference ranges, alert thresholds, and intervention protocols built into CGM platforms were designed for diabetic populations. Applying them to healthy users risks misinterpretation and unnecessary concern.

Johns Hopkins concluded that regular lab screening, specifically fasting glucose and HbA1c testing, remains the most reliable method for assessing metabolic risk in non-diabetics.

Supporting this perspective, an October 2025 systematic review published in Cureus found that while CGM shows promise for personalizing lifestyle interventions in non-diabetics, evidence of direct impact on hard cardiovascular endpoints remains limited. An active Signos clinical trial (NCT05121844, with primary completion expected November 2026) represents one of the few long-term randomized controlled trials working to fill this evidence gap.

Population 1: Prediabetics — The Strongest Case for CGM Use

Prediabetics occupy a clinical gray zone where standard HbA1c and fasting glucose tests may miss early dysglycemia that CGM can detect. This population represents the strongest evidence-based case for non-diabetic CGM use.

The physician argument for CGM in this group centers on early detection. CGM can reveal abnormal blood glucose fluctuations before standard tests show abnormalities, enabling earlier behavioral intervention in a population where over 80% are unaware of their condition.

Research supports this approach. The CGMformer deep-learning model, published in May 2025 by researchers at the University of Illinois at Chicago, demonstrated capability for non-diabetes subtyping and early prediabetes detection using CGM data. A 2025 review on CGM combined with AI for prediabetes management found that deep learning models can identify glucose patterns before HbA1c becomes abnormal.

Most endocrinologists and primary care physicians interviewed in 2026 agree that CGM use in confirmed prediabetics, particularly when paired with a structured lifestyle program and clinical oversight, has the strongest evidence base of any non-diabetic group.

An important caveat remains: even in this group, CGM should complement, not replace, regular HbA1c and fasting glucose testing. The ADA 2026 Standards of Care expanded CGM eligibility for those on non-insulin therapies but have not issued formal endorsement for prediabetic wellness use, leaving physicians to exercise clinical judgment.

Population 2: Metabolically At-Risk Individuals — A Conditional Recommendation

This population includes individuals with obesity, family history of type 2 diabetes, prior gestational diabetes, metabolic syndrome markers, or cardiovascular risk factors who do not yet meet prediabetes criteria.

Given that only approximately 12% of American adults are metabolically healthy, this represents a large population where early metabolic monitoring could theoretically prevent progression to prediabetes or diabetes. Understanding thyroid health and the risk of misdiagnosis is one example of how metabolic conditions can be overlooked without proper clinical evaluation.

A digital health study of 2,217 participants using CGM combined with wearables over 28 days found significant improvements in glucose variability and healthy eating habits, particularly in non-diabetic participants. This suggests CGM-integrated apps can enhance metabolic health when behavioral change is the goal.

Physicians who support CGM in this group emphasize its value as a real-time motivational tool. Seeing glucose spike after a high-carb meal can drive dietary changes more effectively than abstract lab numbers delivered weeks later.

However, physician concerns specific to this group are substantial. Without clinical guidance, metabolically at-risk individuals may misinterpret normal postprandial spikes as pathological, leading to unnecessary anxiety or overly restrictive diets.

The insurance gap presents another barrier. Most insurance plans do not cover OTC CGMs for wellness use, and at $89 to $99 per month, cost creates a significant access issue. The Mass General Brigham study specifically flagged this as a health equity concern.

The physician verdict: CGM may be conditionally appropriate for this group when used under physician supervision, with clear education on normal glucose ranges, and as part of a broader metabolic health program.

Population 3: Healthy Optimizers and Athletes — Where Physician Skepticism Is Strongest

This group includes otherwise healthy adults, such as biohackers, longevity enthusiasts, and competitive athletes, using CGMs for performance optimization, weight management, or general wellness.

The physician consensus here is clear. A survey of four endocrinologists found none recommend CGMs for people without diabetes, with one stating directly that “in people without diabetes who feel well and have no metabolic disease, using a CGM doesn’t add clinical value.”

The Mass General Brigham finding applies directly: in truly healthy individuals, CGM metrics do not correlate with HbA1c. The data may generate noise rather than meaningful signal.

Athletes represent a particularly challenging use case. While CGMs are being used to time carbohydrate intake around workouts and sync meals with circadian rhythms, CGM accuracy is compromised during intense physical activity. This limitation affects the primary use case for this population.

Physicians flag several psychological risks: health anxiety from misinterpreted normal glucose spikes, potential orthorexia or excessive dietary restriction triggered by glucose data, and “glucose fatigue” from data overload. Privacy concerns about cloud-stored continuous biometric data also warrant consideration. The role of nutrition and hormones in metabolic performance is a related area where physician guidance can help athletes make more informed decisions.

Platforms like January AI address some concerns by building predictive metabolic models that reduce the need for permanent CGM wear. However, for truly healthy individuals with no metabolic risk factors, the current evidence does not support routine CGM use.

What Physicians Wish Patients Understood: Five Clinical Realities

Reality 1: Normal spikes are normal. Postprandial glucose rises after meals are physiologically expected in healthy individuals. A CGM reading of 140 to 160 mg/dL after a meal does not indicate a problem in someone without diabetes.

Reality 2: The interpretive framework does not transfer. All clinical thresholds, alert ranges, and intervention protocols in CGM platforms were developed for diabetic populations.

Reality 3: HbA1c and fasting glucose remain the gold standard. Regular lab screening is still the most validated, insurance-covered, and clinically actionable method for assessing metabolic risk in non-diabetics.

Reality 4: The ADA 2026 Standards of Care have not endorsed wellness CGM use. While the standards expanded CGM eligibility for those on therapies, they do not formally endorse CGM for healthy non-diabetic wellness use.

Reality 5: The technology is evolving faster than the evidence. Future CGMs will integrate glucose with ketones, insulin, and hormones, but physicians urge patients to wait for the evidence base to mature.

The Emerging Frontier: Where CGM Technology Is Headed

Physician skepticism today does not mean physician skepticism forever. Next-generation CGMs are expected to combine glucose with ketones, insulin, and hormonal data, providing a far richer metabolic picture.

The Dexcom investment of $75 million into Oura Ring in 2024 made Stelo the only CGM compatible with the Oura smart ring, enabling overlay of glucose data with sleep, activity, and stress metrics. This integration previews the future of comprehensive metabolic monitoring. The growing role of medical technology in personal health management is reshaping how both patients and physicians approach preventive care.

January AI’s digital twin model demonstrates that CGM data combined with machine learning can predict glucose responses 33 hours in advance, potentially making periodic CGM use, rather than continuous wear, a more practical model for non-diabetics.

The active Signos clinical trial results expected by late 2026 could significantly shift the evidence base and physician recommendations for non-diabetic populations.

Conclusion: A Physician-Guided Framework for 2026

The three-population verdict is clear: prediabetics have the strongest evidence-based case for physician-supervised CGM use; metabolically at-risk individuals may benefit conditionally with proper clinical guidance; healthy optimizers face the weakest evidence base and the highest risk of misinterpretation.

The question is not whether CGMs represent impressive technology. They do. The question is whether the data they generate in non-diabetic bodies can be meaningfully interpreted and acted upon without causing harm.

In 2026, the most valuable thing a physician can do is help patients contextualize CGM data, distinguishing normal physiological variation from genuine metabolic signals. As AI integration matures and clinical trials report results, the physician consensus on non-diabetic CGM use will likely evolve.

Talk to Your Doctor Before Buying a CGM

Patients considering an OTC CGM should schedule a conversation with their primary care physician or endocrinologist first, especially those with risk factors for prediabetes or metabolic disease.

A practical starting point is to request a baseline HbA1c and fasting glucose test. This remains the gold standard for metabolic risk assessment and can inform whether CGM monitoring adds value for a specific situation.

Top Doctor Magazine remains committed to bridging the gap between healthcare providers and patients, helping readers make well-informed healthcare decisions grounded in both clinical evidence and physician expertise. Those who know a physician doing exceptional work in metabolic health or diabetes prevention are encouraged to nominate them for a Top Doctor Magazine award or feature.